Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 574-skin-graft-for-skin-ulcer-or-cellulitis-with-cc
    Ask Trek AI about this page

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    DRG 574 applies to inpatient skin grafts for skin ulcers or cellulitis when a Complication or Comorbidity is documented, reflecting higher clinical complexity than cases without such comorbid conditions. This Diagnosis-Related Group influences Medicare inpatient reimbursement by assigning a higher payment weight to account for increased resource use, longer stays, and additional interventions.

    Customize your policy alerts

    Sign up for drg 574 policy alerts

    Get alerted when payer policies referencing 574 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 574 Overview

    DRG 574 covers inpatient admissions for skin graft procedures performed to treat skin ulcers or cellulitis when at least one Complication or Comorbidity is present. Typical cases include surgical debridement and autografting to manage nonhealing pressure, venous, arterial, or diabetic ulcers or extensive infection requiring graft coverage. This Diagnosis-Related Group groups patients with greater resource use than uncomplicated grafts because of increased risk, complexity of wound care, and additional inpatient services. It matters for Medicare payment because the presence of a Complication or Comorbidity elevates relative weight and payment compared with the non-Complication or Comorbidity and Major Complication or Comorbidity categories for similar procedures.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute surgical technique and perioperative care trials: randomized or prospective cohort studies comparing different skin graft techniques (eg, split-thickness vs full-thickness approaches, variations in donor site preparation, or adjunctive intraoperative wound management) and perioperative protocols (eg, antibiotic prophylaxis duration, wound dressing strategies). These trials enroll hospitalized patients with skin ulcers or cellulitis requiring operative debridement and grafting to assess graft take rates, postoperative infection, and early complication rates. Results inform surgeons and hospital administrators on which operative strategies optimize short-term outcomes and resource use for patients classified under this DRG.
    • Comparative effectiveness studies of adjunctive wound therapies during inpatient course: pragmatic trials or observational comparative studies evaluating adjuncts such as negative-pressure wound therapy, biologic skin substitutes, or topical antimicrobial agents used alongside grafting in patients with complex ulcers or infected soft tissue. These studies typically include medically complex, often elderly or diabetic patients with comorbidities that impair healing, and they measure time to successful wound closure, reoperation, length of stay, and readmission. Findings are relevant to payers and providers because they help determine which adjunctive approaches improve healing efficiency and reduce inpatient utilization and downstream costs.
    • Post-discharge outcomes and care coordination research: longitudinal cohort studies or care-pathway trials testing discharge planning, home health integration, and outpatient wound clinic follow-up to reduce readmissions and promote durable graft survival. These studies focus on patients discharged after skin grafting for ulcers or cellulitis, particularly those with social vulnerabilities or limited mobility, tracking wound recurrence, late infections, rehospitalization, and functional status over weeks to months. Evidence from this research informs value-based care strategies, transitional care policies, and reimbursement decisions aimed at lowering preventable readmissions and improving long-term outcomes for this DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.